BioCentury | Feb 28, 2020
Distillery Therapeutics

Boosting OSM and TIMP1 levels to treat demyelinating diseases

...DISEASE CATEGORY: Autoimmune disease INDICATION: Multiple sclerosis (MS) Promoting expression of OSM or its downstream mediator...
...of a lentiviral vector encoding OSM increased remyelination and the number of mature oligodendrocytes. TARGET/MARKER/PATHWAY: Oncostatin M (OSM)...
...online Feb. 18, 2020 doi:10.1073/pnas.1912910117 CONTACT: Niels Hellings, University of Hasselt, Diepenbeek, Belgium email: niels.hellings@uhasselt.be Claire Quang Oncostatin M (OSM) Tissue...
BioCentury | May 4, 2018
Financial News

Ex-Synageva team planning Kiniksa IPO

...Biogen Inc. (NASDAQ:BIIB). The therapy is a mAb that inhibits IL-31 and oncostatin M (OSM) by targeting oncostatin M...
BioCentury | Apr 28, 2018
Financial News

Ex-Synageva team planning Kiniksa IPO

...Biogen Inc. (NASDAQ:BIIB). The therapy is a mAb that inhibits IL-31 and oncostatin M (OSM) by targeting oncostatin M...
BioCentury | Jun 7, 2017
Distillery Therapeutics

Autoimmune disease

...suggest inhibiting OSM could help treat IBD. In a mouse model of chemically induced colitis, OSM...
...inhibits OSM decreased colonic inflammation compared with an unrelated control protein. Next steps include testing OSM...
...in other IBD models (see "A Window to IBD." BioCentury Innovations (May 4, 2017)). TARGET/MARKER/PATHWAY: Oncostatin M (OSM)...
BioCentury | May 4, 2017
Translation in Brief

A window to IBD

...as well as other inflammatory diseases. In the study, the group found OSM and the oncostatin M...
...disease severity. Patients who had the highest expression levels of OSM, or a set of OSM-induced...
...a larger prospective study to confirm OSM's potential as a biomarker. West, N., et al. "Oncostatin M...
BioCentury | Dec 20, 2016
Distillery Therapeutics

Hepatic

...Cancer Center Research Institute, Tokyo, Japan email: tochiya@ncc.go.jp Hongjiang Li Japanese National Cancer Center Glycogen dependent kinase 3 (GSK3) Oncostatin M (OSM) Rho-associated...
BioCentury | Dec 17, 2015
Distillery Techniques

Techniques: Expansion and differentiation of functional primary human hepatocytes for in vitro disease modeling

...with E6 transforming protein (Human papillomavirus-16)(HpV16gp1) and E7 transforming protein (Human papillomavirus-16)(HpV16gp2) and treating with oncostatin M (OSM)...
...MEK2 ) inhibitor. Cells proliferated for 30-40 generations and differentiated into functional, polarized hepatocytes after OSM...
BioCentury | Oct 8, 2015
Distillery Therapeutics

Therapeutics: Oncostatin M (OSM)

...suggest OSM could help treat stroke. In mouse and rat models of stroke, levels of OSM...
...cerebral artery occlusion than before. In the mouse model of stroke, transgenic expression of human OSM...
...compared with vehicle. Next steps could include testing OSM in additional models of stroke. TARGET/MARKER/PATHWAY: Oncostatin M (OSM)...
BioCentury | Dec 13, 2012
Distillery Therapeutics

Indication: Cancer

...Cancer Lung cancer Oncostatin M (OSM) Mouse studies suggest the cytokine OSM could help treat lung cancer. OSM...
...cultured human lung cancer cell lines, OSM inhibited migration and invasion. In mice, injection of OSM-pretreated...
...tumor growth and metastasis compared with vehicle injection. Next steps include evaluating the combination of OSM...
BioCentury | Jan 21, 2010
Targets & Mechanisms

Oncostatin's LIFR sentence

...inhibitory factor receptor-a (LIFR; CD118 ) without affecting binding between OSM and oncostatin M receptor (OSMR). OSM...
...OSMR 3 "The role of oncostatin M in bone formation"). see Figure 1, "The role of oncostatin M...
...team was generating Osmr knockout mice. Previous studies have shown that mouse Osm, unlike human OSM...
Items per page:
1 - 10 of 11